$CLRB
Cellectar Biosciences, Inc.

2015 Q4 Form 10-Q Financial Statement

#000114420415064694 Filed on November 12, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $800.0K $830.0K $850.0K
YoY Change -5.88% 3.75% -39.72%
% of Gross Profit
Research & Development $960.0K $1.168M $1.400M
YoY Change -31.43% -20.58% -9.68%
% of Gross Profit
Depreciation & Amortization $90.00K $90.00K $90.00K
YoY Change 0.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $1.770M $1.168M $2.250M
YoY Change -21.33% -20.58% -23.99%
Operating Profit -$2.093M
YoY Change -7.94%
Interest Expense $2.740M $617.00 -$1.090M
YoY Change -351.38% -100.24% -1090.91%
% of Operating Profit
Other Income/Expense, Net $234.3K
YoY Change -90.98%
Pretax Income $950.0K -$1.860M -$3.350M
YoY Change -128.36% -681.25% -15.19%
Income Tax
% Of Pretax Income
Net Earnings $950.0K -$1.858M -$3.350M
YoY Change -128.36% -673.49% -15.19%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $10.56M -$23.25M -$41.88M
COMMON SHARES
Basic Shares Outstanding 8.581M shares 7.564M shares 7.563M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.860M $2.470M $9.420M
YoY Change -59.02% -78.67% 289.26%
Cash & Equivalents $3.913M $2.473M $9.423M
Short-Term Investments
Other Short-Term Assets $330.0K $510.0K $280.0K
YoY Change 17.86% 45.71% -20.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.180M $2.973M $9.698M
YoY Change -56.9% -75.06% 250.36%
LONG-TERM ASSETS
Property, Plant & Equipment $1.728M $1.801M $2.034M
YoY Change -15.02% -14.68% -13.84%
Goodwill $1.675M $1.675M $1.675M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $11.87K $11.87K $11.87K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $3.416M $3.489M $3.721M
YoY Change -8.19% -8.16% -8.07%
TOTAL ASSETS
Total Short-Term Assets $4.180M $2.973M $9.698M
Total Long-Term Assets $3.416M $3.489M $3.721M
Total Assets $7.596M $6.462M $13.42M
YoY Change -43.39% -58.9% 96.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $680.0K $580.0K $930.0K
YoY Change -26.88% -49.12% -19.83%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $250.0K $240.0K $120.0K
YoY Change 108.33% 118.18%
Total Short-Term Liabilities $5.700M $5.476M $6.233M
YoY Change -8.55% 165.15% 37.8%
LONG-TERM LIABILITIES
Long-Term Debt $90.00K $160.0K $340.0K
YoY Change -73.53% -55.56% -24.44%
Other Long-Term Liabilities $150.0K $150.0K $150.0K
YoY Change 0.0% 0.0% 7.14%
Total Long-Term Liabilities $240.0K $305.8K $489.0K
YoY Change -50.92% -39.46% -17.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.700M $5.476M $6.233M
Total Long-Term Liabilities $240.0K $305.8K $489.0K
Total Liabilities $5.950M $5.781M $6.722M
YoY Change -11.48% 124.94% 31.38%
SHAREHOLDERS EQUITY
Retained Earnings -$64.61M -$65.56M -$59.11M
YoY Change 9.3% 15.84% 15.77%
Common Stock $76.00 $76.00
YoY Change 0.0% 162.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.650M $680.2K $6.698M
YoY Change
Total Liabilities & Shareholders Equity $7.600M $6.462M $13.42M
YoY Change -43.37% -58.9% 96.88%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q4
OPERATING ACTIVITIES
Net Income $950.0K -$1.858M -$3.350M
YoY Change -128.36% -673.49% -15.19%
Depreciation, Depletion And Amortization $90.00K $90.00K $90.00K
YoY Change 0.0% 0.0% 0.0%
Cash From Operating Activities -$1.490M -$2.170M -$2.140M
YoY Change -30.37% 3.33% -19.85%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K -$10.00K -$10.00K
YoY Change 100.0% -50.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$20.00K -$10.00K -$10.00K
YoY Change 100.0% -50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.900M -190.0K 0.000
YoY Change -101.58%
NET CHANGE
Cash From Operating Activities -1.490M -2.170M -2.140M
Cash From Investing Activities -20.00K -10.00K -10.00K
Cash From Financing Activities 2.900M -190.0K 0.000
Net Change In Cash 1.390M -2.370M -2.150M
YoY Change -164.65% -123.84% -20.07%
FREE CASH FLOW
Cash From Operating Activities -$1.490M -$2.170M -$2.140M
Capital Expenditures -$20.00K -$10.00K -$10.00K
Free Cash Flow -$1.470M -$2.160M -$2.130M
YoY Change -30.99% 2.86% -19.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11872 USD
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11872 USD
CY2014Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
2180 USD
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5475576 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6233006 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
9698238 USD
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1801365 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2033944 USD
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
220611 USD
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
445281 USD
CY2015Q3 us-gaap Goodwill
Goodwill
1675462 USD
CY2015Q3 us-gaap Assets Current
AssetsCurrent
2972808 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.31
us-gaap Costs And Expenses
CostsAndExpenses
6971054 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7637932 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2932705 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.85
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
526024 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
3368977 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-913 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-436272 USD
us-gaap Net Income Loss
NetIncomeLoss
-6445943 USD
us-gaap Net Income Loss
NetIncomeLoss
-4705227 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
525111 USD
CY2015Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
2384 USD
CY2015Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
147919 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1470297 USD
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
834888 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
802794 USD
CY2015Q3 us-gaap Restructuring Costs
RestructuringCosts
89848 USD
CY2014Q3 us-gaap Restructuring Costs
RestructuringCosts
0 USD
CY2015Q3 us-gaap Costs And Expenses
CostsAndExpenses
2092504 USD
CY2014Q3 us-gaap Costs And Expenses
CostsAndExpenses
2273091 USD
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2092504 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2273091 USD
CY2014Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
2850171 USD
CY2015Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
617 USD
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2597113 USD
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.06
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7563701 shares
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5012206 shares
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4194727 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4566403 USD
us-gaap Restructuring Costs
RestructuringCosts
180348 USD
us-gaap Restructuring Costs
RestructuringCosts
221815 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
426458 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-858 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2269 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-354067 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-22594 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
95014 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6718646 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6699273 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
6697533 USD
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6461507 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59111670 USD
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
680151 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2849714 USD
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
234266 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
324022 USD
CY2015Q3 us-gaap Assets
Assets
6461507 USD
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
933988 USD
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
147774 USD
CY2015Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
8612 USD
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
11126 USD
CY2015Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
305780 USD
CY2014Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
488977 USD
CY2015Q3 us-gaap Liabilities
Liabilities
5781356 USD
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
76 USD
CY2015Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
66237688 USD
CY2014Q4 us-gaap Liabilities
Liabilities
6721983 USD
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1167768 USD
CY2014Q4 us-gaap Assets
Assets
13419516 USD
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
65809127 USD
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65557613 USD
CY2015Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q3 us-gaap Notes Payable Current
NotesPayableCurrent
242380 USD
CY2014Q4 us-gaap Notes Payable Current
NotesPayableCurrent
119923 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13419516 USD
CY2015Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
579812 USD
CY2015Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
55000 USD
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
55000 USD
CY2015Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
4651000 USD
CY2014Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
5176915 USD
CY2014Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
330077 USD
CY2015Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
149249 USD
CY2014Q4 us-gaap Goodwill
Goodwill
1675462 USD
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
76 USD
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-1858238 USD
CY2014Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-253058 USD
CY2015Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
233649 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4335 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17397 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
2310 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6950100 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2418384 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-1475 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6971054 USD
CY2014Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1598689 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
271508 USD
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Amendment Flag
AmendmentFlag
false
us-gaap Share Based Compensation
ShareBasedCompensation
428561 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7563078 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3591742 shares
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
277688 USD
us-gaap Share Based Compensation
ShareBasedCompensation
682775 USD
us-gaap Costs And Expenses
CostsAndExpenses
7637932 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
719466 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.20
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
dei Entity Registrant Name
EntityRegistrantName
Cellectar Biosciences, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001279704
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
CLRB
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8581405 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
39787 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-39787 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-17397 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4000000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1694 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-191667 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
15874291 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
9157621 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11576005 USD
clrb Debt Conversion Converted Instrument Value Warrants Issued
DebtConversionConvertedInstrumentValueWarrantsIssued
0 USD
clrb Debt Conversion Converted Instrument Value Warrants Issued
DebtConversionConvertedInstrumentValueWarrantsIssued
254024 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-4000 USD
us-gaap Interest Paid
InterestPaid
43597 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
59701 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
clrb Proceeds From Deferred Issuance Costs
ProceedsFromDeferredIssuanceCosts
-129656 USD
clrb Proceeds From Deferred Issuance Costs
ProceedsFromDeferredIssuanceCosts
0 USD
clrb Reverse Stock Split Fractional Shares
ReverseStockSplitFractionalShares
0 USD
clrb Reverse Stock Split Fractional Shares
ReverseStockSplitFractionalShares
1158 USD
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.873 pure
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y4M20D
CY2014Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
13475832 USD
CY2014Q3 us-gaap Proceeds From Repurchase Of Equity
ProceedsFromRepurchaseOfEquity
11877143 USD
CY2015Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6597483 shares
CY2015Q3 us-gaap Share Based Compensation
ShareBasedCompensation
165016 USD
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
146559 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
510200 shares
clrb Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
149177 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
283773 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
788383 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.59
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.67
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
253556 shares
CY2015Q3 clrb Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Unvested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedOutstandingNumber
534827 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
253556 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
18.04
CY2015Q3 clrb Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedExercisableWeightedAverageExercisePrice
3.04
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
18.04
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2015Q3 clrb Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue
0 USD
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y7M10D
clrb Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageRemainingContractualTerm
P9Y6M22D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M10D
clrb Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice
22.68
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.22
CY2015Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
971000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Current Year
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInCurrentYear
99000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Two
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearTwo
318000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Three
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearThree
258000 USD
CY2015Q3 clrb Share Based Compensation Arrangement By Sharebased Payment Award Options Unvested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestOutstandingNumber
534827 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
45000 shares
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Four
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearFour
206000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Five
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearFive
90000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
clrb Amount Invoiced Under Clinical Trial Agreements
AmountInvoicedUnderClinicalTrialAgreements
479496 USD
clrb Payment Towards Clinical Trial Agreements
PaymentTowardsClinicalTrialAgreements
460356 USD
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000 shares
CY2015Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7564133 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7562762 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7564133 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7562762 shares
CY2015Q3 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
55000 USD
CY2015Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
5493023 shares
CY2014Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
5494388 shares
CY2014Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
55000 USD
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.82 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0176 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.08 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.17
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
617500 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
518822 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
4172444 USD
clrb Fair Value Of Warrants Classified As Derivative Liability
FairValueOfWarrantsClassifiedAsDerivativeLiability
0 USD
clrb Fair Value Of Warrants Classified As Derivative Liability
FairValueOfWarrantsClassifiedAsDerivativeLiability
4102709 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12395965 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
617500 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
8333 shares
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.74
CY2014Q3 clrb Warrants Exercise Price
WarrantsExercisePrice
0.01
clrb Annual Forfeiture Rate Percentage
AnnualForfeitureRatePercentage
0.02 pure
CY2014 clrb Annual Forfeiture Rate Percentage
AnnualForfeitureRatePercentage
0 pure
CY2015Q3 clrb Stockholders Equity Description
StockholdersEquityDescription
the Company received a notice from Nasdaq of non-compliance with its continuing listing rules, namely that our stockholders’ equity at June 30, 2015 of $2,373,371, as reported in our Form 10-Q for the quarter then ended, was less than their required $2,500,000 minimum. The failure to meet continuing compliance standards subjects the Company’s common stock to delisting. The Company has requested, and the Nasdaq Staff has granted, an extension of time to effect transactions to allow the Company to regain compliance and to report the same in the Company’s annual report on Form 10-K for the year ended December 31, 2015.

Files In Submission

Name View Source Status
0001144204-15-064694-index-headers.html Edgar Link pending
0001144204-15-064694-index.html Edgar Link pending
0001144204-15-064694.txt Edgar Link pending
0001144204-15-064694-xbrl.zip Edgar Link pending
clrb-20150930.xml Edgar Link completed
clrb-20150930.xsd Edgar Link pending
clrb-20150930_cal.xml Edgar Link unprocessable
clrb-20150930_def.xml Edgar Link unprocessable
clrb-20150930_lab.xml Edgar Link unprocessable
clrb-20150930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v423834_10q.htm Edgar Link pending
v423834_ex31-1.htm Edgar Link pending
v423834_ex31-2.htm Edgar Link pending
v423834_ex32-1.htm Edgar Link pending